PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsewing sarcoma
MeSH D012512 - ewing sarcoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D012516:Osteosarcoma
$
Success rate
D012512: 
Ewing sarcoma
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaEtoposide Etoposide  1994-02-10   
Cyclophosphamide Neosar  1993-04-29   
Etoposide Toposar  1995-02-27   
IngenusCyclophosphamide Cyclophosphamide 2036-02-15 2020-07-30   
MylanEtoposide Etoposide  2001-09-19   
CiplaCyclophosphamide Cyclophosphamide  2019-01-18   
Alembic PharmaceuticalsCyclophosphamide Cyclophosphamide  2022-11-10   
HospiraEtoposide Etoposide  1995-08-30   
Amneal PharmaceuticalsCyclophosphamide Cyclophosphamide  2018-05-25   
Strides Pharma GlobalEtoposide Vepesid  1986-12-30   
Bristol Myers SquibbEtoposide Etopophos  1998-02-27   
Accord HealthcareEtoposide Etoposide  1996-03-14   
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
73%
40/55
Phase 2
13%
9/72
Phase 3
24%
5/21
Approved: 3Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
1
2
3
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use